3600 Gilmore Way
Unit 302
Burnaby, BC V5G 4W8
Canada
https://www.geminalabs.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 6
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Mr. Brian Firth | CEO & Director | N/A | N/A | N/A |
Mr. Michael Liggett B.Sc., Bsc. Pharm., C.A., C.P.A., CA, CPA | CFO & Company Secretary | N/A | N/A | 1960 |
Dr. Robert Crandall Greene | CTO & Director | N/A | N/A | N/A |
Mr. Hugh McNaught | VP of Marketing & Member of Advisory Board | N/A | N/A | N/A |
Mr. David Browning FCIM, M.Sc. | Head of Productization & Director of Gemina Laboratories (UK) Limited | N/A | N/A | N/A |
Dr. Christine Buerki Ph.D. | Head of Product Development | N/A | N/A | N/A |
Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company develops Legio X, a COVID-19 rapid antigen test that validating the Gemina Surface Chemistry on this platform; and LEGIO X, an influenza AB multiplex lateral flow test. It is also developing a pipeline of products for the diagnosis of infectious respiratory diseases. The company was incorporated in 2017 and is headquartered in Burnaby, Canada.
Gemina Laboratories Ltd.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.